Abemacyclib - Anyone on its trials?

Options
Punam
Punam Member Posts: 8
edited September 2016 in Stage IV/Metastatic Breast Cancer ONLY

During my visit to my MO, he mentioned about Abemacyclib. He was very upbeat about this new deug. As per him it is going to be a superior drug them Palbocyclib (Ibrance) which can be used as a single drug too and without any major side effects. The trials for the same are expected in India in Jan 2017. I understand from him that the drug is already in trials in u.s.

Please let me know if anyone is taking this drug under any trial program and what are the results

· Share on FacebookShare on Twitter

Comments

  • Longtermsurvivor
    Longtermsurvivor Member Posts: 1,438
    edited August 2016

    HI Punam,

    Abemaciclib is a CDK inhibitor like palbociclib.

    Here's a post specifically about it and the trial you mentioned:

    MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease.

    You may want to visit the palbociclib (aka Ibrance) topic here at:

    https://community.breastcancer.org/forum/8/topics/...

    It's good to meet you and I hope you get more information from others here who may be participating in this or other trials.

    warmest healing wishes, Punam, Stephanie

    · Share on FacebookShare on Twitter
  • Punam
    Punam Member Posts: 8
    edited August 2016

    Thanks Stephanie for the link. It sure has a lot of useful information

    · Share on FacebookShare on Twitter
  • Longtermsurvivor
    Longtermsurvivor Member Posts: 1,438
    edited September 2016

    Lilly Cancer Drug Hits Hurdle, Panel Recommends Study Continue

    By Reuters Staff

    August 11, 2016

    (Reuters)

    An independent panel's interim analysis of Eli Lilly and Co's breast cancer drug abemaciclib showed the treatment did not meet the effectiveness criteria in a late-stage trial.

    The panel recommended the trial continue through the first half of 2017, the company said on Wednesday.

    If approved, abemaciclib is expected to compete with Pfizer Inc's breast cancer drug, Ibrance (palbociclib), which brought in over half a billion dollars in second-quarter sales.

    The trial is designed to evaluate the safety and efficacy of abemaciclib, in combination with anti-estrogen drug fulvestrant, in patients with a form of advanced breast cancer.

    Lilly, which said it remained optimistic the combination could benefit patients, is also evaluating abemaciclib as a single agent in refractory metastatic breast cancer in patients who have not derived enough benefit from prior treatments.

    Three other studies are testing abemaciclib with other drugs for various forms of breast cancer.

    The drug, which was granted the U.S. Food and Drug Administration's (FDA) breakthrough therapy status for breast cancer last year, is also being tested for use in lung cancer.

    After skin cancer, breast cancer is the most common cancer among women in the United States, according to the U.S. Centers for Disease Control and Prevention (CDC).

    About 40,000 of the 220,000 American women diagnosed with breast cancer die each year, the agency estimates.

    · Share on FacebookShare on Twitter

Categories